Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
18 janv. 2022 07h00 HE
|
Sema4
Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify...
LifeBank Chain Brings Ultimate Gene and Cell Therapy Benefits to Everyone
12 janv. 2022 11h00 HE
|
LifeBank Chain
JERUSALEM, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Recently, a start-up project "LifeBank Chain (LBC)" in Israel is utilizing advanced gene and cell technologies over blockchain to develop advanced...
FDA Pre-Submission Filed for Cardio inCode-SCORE
11 janv. 2022 02h30 HE
|
GENinCode Plc
OXFORD, England, Jan. 11, 2022 (GLOBE NEWSWIRE) -- GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the filing of its...
Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021
10 janv. 2022 07h15 HE
|
Sema4
STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced preliminary revenue (unaudited) for the...
Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January
03 janv. 2022 16h05 HE
|
Sema4
STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that Eric Schadt, PhD, Founder and...
Inagene Diagnostics Inc. provides personalized medicine with genetic guidance to medical cannabis users
18 nov. 2021 06h00 HE
|
Inagene Diagnostics Inc.
TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Since cannabis legalization in 2018, interest in its medical application has been skyrocketing. Canadian consumers and health care providers seek guidance...
Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights
15 nov. 2021 16h01 HE
|
Sema4
36% increase in test volume (excluding COVID-19 tests) compared to the same period last year 17% growth in revenue (excluding COVID-19 tests) compared to the same period last year ...
Inagene Diagnostics Inc.’s CEO featured alongside global expert advocates highlighting pharmacogenomic (gene-drug compatibility) testing as a game-changing innovation to safeguard the health of Canadians
09 nov. 2021 06h00 HE
|
Inagene Diagnostics Inc.
TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Focused on The Future of Innovation, Personalized Medicine and Genomics, the 21st Annual Healthcare Summit brought together global healthcare experts,...
Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction
04 nov. 2021 08h00 HE
|
Sema4
STAMFORD, Conn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, recently published two studies demonstrating the...
Inagene Diagnostics Inc. and Granville Biomedical Inc. team up to provide locally-produced pharmacogenetic testing kits to Canadians
01 nov. 2021 06h00 HE
|
Inagene Diagnostics Inc.
TORONTO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Canadian pharmacogenetic (PGx) testing provider, Inagene Diagnostics Inc., has partnered with fellow Canadian health-tech company, Granville Biomedical...